Close

Not a member yet? Register now and get started.

lock and key

Sign in to your account.

Account Login

Forgot your password?

Equipment & Services  // Browsing posts in Equipment & Services

Abiomed Idea Proposal

Abiomed Idea Proposal

Research Question: Will the Impella propel Abiomed to achieve its 40% growth projections? Report Available: October 14, 2015   Blueshift’s initial research shows ABMD’s Impella utilization rate is increasing faster than many had expected in its Q1. ABMD, a leader in heart support technologies, then issued an aggressive five-year strategy which predicted $1.2 billion to $1.8 billion in […]

Read more...

Exact Sciences’ Cologuard the Preferred Test for Patients Refusing Colonoscopy (EXAS)

Research Question: Will Exact Sciences’ Cologuard become physician’s screening test of choice for colon cancer? Companies: ABT, BDX, BIOC, BSX, CHEK, CPHD, DGX, EXAS, FMI, GIVN, GSK, IRWD, RHHBY By: David Franklin Click here to download the report (.pdf)   Summary of Findings Exact Sciences Corp.’s (EXAS) Cologuard has high clinical value, but it is unlikely […]

Read more...

Exact Sciences Whisper

Exact Sciences Whisper

Research Question: Will Exact Sciences’ Cologuard become the colon cancer screening test of choice for physicians? Report Available: August 14, 2015   Blueshift’s initial research shows EXAS’s Cologuard, a non-invasive test for colon cancer, is monetizing at a significant rate following FDA approval and an increased sales staff. But some physicians argue the screener should not be […]

Read more...

Medtronic Whisper

Medtronic Whisper

Research Question: Will Medtronic’s Covidien Solitaire, a neurovascular stent, become the new standard procedure for stroke treatments? Companies Covered: Medtronic (MDT), Stryker (SYK), Johnson and Johnson (JNJ), Boston Scientific (BSX)​ Report Available: April 17, 2015   Blueshift’s initial research shows that the Solitaire neurovascular stent is regarded as a game changer by several medical experts. […]

Read more...

Zeltiq’s CoolSculpting System and Treatment Sales Expected to Grow

Research Question: Will Zeltiq continue growing system sales and increasing procedure volume for its CoolSculpting system, or is it a fad? Companies: CUTR, ELOS, LMNS, VRX, ZLTQ By: David Franklin Click here to download the report (.pdf)   Summary of Findings Zeltiq Aesthetics Inc.’s (ZLTQ) CoolSculpting procedure is considered the industry-leading noninvasive fat reduction system. CoolSculpting system […]

Read more...

Zeltiq Aesthetics Whisper

Zeltiq Aesthetics Whisper

Research Question: Will ZLTQ continue growing system sales and increasing procedure volume for its CoolSculpting system, or is it a fad? Companies Covered: Zeltiq Aesthetics (ZLTQ), Cynosure (CYNO), Cutera (CUTR), Syneron Medical (ELOS), Lumenis (LMNS), Valeant (VRX) Report Available: February 17, 2015   Blueshift’s initial research shows ZLTQ’s CoolSculpting procedure continuing to rapidly grow in […]

Read more...

FDA Approval Gives Spectranetics a Window for Moderate Sales Growth

Research Question: Will Spectranetics’ laser atherectomy and PTA become the new standard of treatment for femoropopliteal ISR and be the catalyst for a significant revenue boost? Companies: ABT, BCR, COV, JNJ, SPNC, VOLC By: David Franklin Click here to download the report (.pdf)   Summary of Findings Spectranetics Corp. (SPNC) can expect a moderate sales increase as […]

Read more...

Although Not to Forecast Level, MDSO’s CTMS Sales Will Grow This Year

Research Question: Can Medidata capitalize on a stronger sales pipeline to reach its projected growth of 20% to 25% despite challenges from innovative competitors? Companies: IBM, MDSO, MRGE, ORCL, QCOM, PRXL By: David Franklin Click here to download the report (.pdf)   Summary of Findings As Blueshift Research found in its Dec. 13, 2013, report, Medidata Solutions Inc. […]

Read more...

Spectranetics Whisper

Spectranetics Whisper

Research Question: Will superior results from the recent EXCITE ISR trial ensure FDA approval and provide a significant revenue boost for Spectranetics? Companies Covered: Spectranetics Corporation (SPNC) Report Available: August 14, 2014   Blueshift’s initial research shows a substantial market for the treatment of Femoropopliteal In-Stent Restenosis with the combination of SPNC’s laser atherectomy and percutaneous transluminal […]

Read more...

ISRG’s da Vinci Xi and International Focus Unlikely to Spur Growth

Research Question: Will the new da Vinci Xi robot and a company focus on international growth lead to a turnaround for Intuitive Surgical? Companies: CVE:TMD, ISRG By: David Franklin Click here to download the report (.pdf)   Summary of Findings Intuitive Surgical Inc.’s (ISRG) new da Vinci Xi System and the initiative to increase international sales and surgical […]

Read more...